InFlectis BioScience SAS, a clinical-stage company developing innovative therapeutics for neuromuscular diseases by harnessing the Integrated Stress Response (ISR), dosed the first patient with IFB-088 in combination with riluzole as part of the phase 2 clinical trial for the treatment of bulbar-onset Amyotrophic Lateral Sclerosis (ALS), a rare neurological disease with no curative treatment to date.
Nantes, France--(Newsfile Corp. - December 19, 2022) - InFlectis BioScience SAS, a clinical-stage company developing innovative therapeutics for neuromuscular diseases by harnessing the Integrated Stress Response (ISR), dosed the first patient with IFB-088 in combination with riluzole as part of the phase 2 clinical trial for the treatment of bulbar-onset Amyotrophic Lateral Sclerosis (ALS), a rare neurological disease with no curative treatment to date.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- The first patient has been dosed in the phase 2 study of IFB-088, a potential first-in-class Integrated Stress Response modulator.
- This is multi-center, double-blind, placebo-controlled, randomized clinical trial in patients with bulbar-onset ALS.
- Enrollment will continue across 17 sites in France and Italy in a minimum of 50 patients.
Click image above to view full announcement.
About InFlectis BioScience
InFlectis BioScience is a France-based clinical stage company developing first-in-class therapies for neuromuscular diseases. InFlectis BioSciences’ therapies are designed to boost a cellular command center - called the Integrated Stress Response - that ensures healthy levels of proteins and protein structures. Excessive and prolonged cellular stress can overwhelm this command center, resulting in the loss of functional cells and onset or progression of neuromuscular diseases. The Company’s compounds are designed to keep this command center operating and to prevent downstream effects that lead to disease.
Contacts:
Francina Agosti, Ph.D.
francina@octaviant.com
Source: Inflectis
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/148572
